65,437 trials
Back Strain · Neck Strain
Primary: Pain Score After Treatment — 66; 64 mm
Chronic Migraine
Primary: Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7. — -7.61; -6.67; -9.72; -5.22 days
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
Hot Flashes
Primary: Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment — -7.0; -6.9; -5.4 Hot flashes — p=0.0024
Glioma · Medulloblastoma
Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants
Pneumococcal Infections
Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…
Presbyopia · Myopia
Primary: End of Day Comfort — 7.7; 7.2 Units on a scale
Diabetes Mellitus, Type 2
Primary: Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels — -85.7; -117.4; -99.6 mg/dL — p=0.002
Chronic Obstructive Pulmonary Disease
Primary: Peak Inspiratory Capacity (IC) After 21 Days of Treatment — 2.69; 2.48; 2.63 Liters
Obstetric Labor Complications · Preeclampsia · Thrombocytopenia
Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts
Dyslipidemia
Primary: Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period — 291; 181; 188; 43…
Kidney Cancer
Primary: Maximum Tolerated Dose (MTD) of Erlotinib Hydrochloride When Used in Combination With Sunitinib. — 50; 150 milligrams
Waldenstrom's Macroglobulinemia
Primary: Overall Response (OR) Rate — 38 percentage of patients
Post Operative Pain
Primary: Mean of 4 NRS Scores for 24 Hour Pain Intensity at Rest, Shown as Absolute Change From Baseline (i.e. a Decrease From the Baseline Value) — -1.2; -1.1 Units on a scale
Adult Meningioma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 0 Participants